BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)

Background: Advances in antiemetic supportive care have led to remarkable improvements in the prevention of CINV, with evidence-based antiemetic guidelines, such as NCCN, recommending multi-agent prophylactic combinations that target different receptors. Clinical trials have confirmed the superiority of triple combination regimens (an NK 1 receptor antagonist [NK 1 RA], a 5-HT 3 RA, and dexamethasone [DEX]) over a 5-HT 3 RA + DEX. Thus, a triple combination is indicated for patients receiving HEC. In the clinical development program of NEPA, 3 HEC (cisplatin-based) registration studies included an NK 1 RA (aprepitant; APR) + 5-HT 3 RA + DEX arm. This post-hoc analysis evaluated the efficacy of NEPA versus APR across the cisplatin trials. Methods: Chemotherapy-naïve patients in 3 randomized, double-blind, multinational trials received a single oral dose of NEPA + DEX prior to cisplatin on Day 1 or a 3-day APR comparator/control regimen. All patients in both groups also received DEX on Days 2-4. Inclusion/exclusion criteria were similar across studies. Data from the 3 studies were pooled for efficacy endpoints of: 1) complete response (CR: no emesis, no rescue medication); 2) no significant nausea (NSN: max <25 mm on 100 mm VAS); and 3) complete protection (CP: no emesis, no rescue and NSN) for the post-chemotherapy acute (0-24 h), delayed (25-120 h) and overall (0-120 h) phases. Treatments and associated risks were compared using generalized linear models with log-link function and binomial distribution (log-binomial model). Results: In this pooled analysis, 621 patients received NEPA and 576 received APR. Although response rates were similar for the acute phase, delayed and overall phase responses favored NEPA (Table). Conclusions: Based on the current pooled analysis of Phase 3, cisplatin-based studies, oral NEPA administered on Day 1 only was more effective than a 3-day APR regimen in preventing delayed and overall CINV from HEC. NEPA, a fixed oral combination of an NK 1 RA/5HT 3 RA in a single capsule administered only once per cycle, offers clinicians a simple, convenient, and highly effective prophylactic combination antiemetic concordant with guidelines. Other potential benefits include reducing healthcare costs associated with decreased acute-care use related to delayed CINV, and minimizing the risk for suboptimal patient adherence to antiemetics.


If the inline PDF is not rendering correctly, you can download the PDF file here.

Corresponding Author: Rudolph M. Navari, MD, PhD
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 30 30 30
PDF Downloads 90 90 90
EPUB Downloads 0 0 0